tetrahydro-cyclopenta[b]pyrrole-2-carboxylic acid ethyl ester | 124455-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: tetrahydro-cyclopenta[b]pyrrole-2-carboxylic acid ethyl ester
• 英文别名: ethyl 1,4,5,6-tetrahydrocyclopentadieno[b]pyrrole-2-carboxylate；ethyl 1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylate
• CAS: 124455-77-2
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: BCKKFUQZDGWAJE-UHFFFAOYSA-N

物化性质

• 沸点：
  351.4±42.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetrahydro-cyclopenta[b]pyrrole-2-carboxylic acid ethyl ester 在 吡啶 、 lithium hydroxide 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 水 为溶剂， 反应 19.0h， 生成 3-phenyl-2(RS)-{2-[(1,4,5,6-tetrahydro-cyclopenta[b]pyrrole-2-carbonyl)-amino]-benzoylamino}-propionic acid ethyl ester
  参考文献：
  名称：

  Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a “needle” according to the recent homonymous concept

  摘要：

  Recently we described an innovative class of non-peptide CCK1 antagonists keeping appropriate pharmacophoric groups on the anthranilic acid employed as a molecular scaffold. The lead compound obtained, VL-0395, characterized by the presence of Phe and the 2-indole moiety at the C- and N-termini of anthranilic acid, respectively, is endowed with submicromolar affinity towards CCK1 receptors. Thus, we have prepared and tested on CCK receptors a library of VL-0395 analogues in order to investigate the precise topological and essential key interactions of the 2-indole group of the lead with the CCK1 receptor. The obtained results confirm that this group establishes very specific interactions with this receptor sub-site and may be viewed as a "needle" group. (C) 2003 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2003.11.010
• 作为产物：
  描述：

  ethyl 3-(2-azidocyclopent-1-enyl)-3-hydroxypropionate 在 吡啶 、 三氯氧磷 作用下， 以 xylene 、 苯 为溶剂， 反应 21.0h， 生成 tetrahydro-cyclopenta[b]pyrrole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Aubert, Thierry; Tabyaoui, Badia; Farnier, Michel, Journal of the Chemical Society. Perkin transactions I, 1989, p. 1369 - 1373

  摘要：

  DOI：

文献信息

• [EN] HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES HÉTÉROARYLES ET LEURS UTILISATIONS
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2021164735A1

  公开（公告）日：2021-08-26

  Provided herein are heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the variables are as defined in the description.

  本文提供了公式（I）的杂环杂芳基化合物，包括这些化合物的药物组合物，制备这些化合物的方法以及它们的用途，其中变量如描述中所定义。
• (<i>E</i>)-3-(2-(<i>N</i>-Phenylcarbamoyl)vinyl)pyrrole-2-carboxylic Acid Derivatives. A Novel Class of Glycine Site Antagonists
  作者：Cesarino Balsamini、Annalida Bedini、Giuseppe Diamantini、Gilberto Spadoni、Andrea Tontini、Giorgio Tarzia、Romano Di Fabio、Aldo Feriani、Angelo Reggiani、Giovanna Tedesco、Roberta Valigi

  DOI：10.1021/jm970416w

  日期：1998.3.1

  biological evaluation of novel (E)-3-(2-(N-phenylcarbamoyl)-vinyl)pyrrole-2-carboxylic acids bearing alkyl, acyl, alkoxy, phenyl, and halo substituents at the 4- and 5-positions of the pyrrole ring are reported. These compounds were studied for their in vitro affinity at the strychnine-insensitive glycine-binding site of the N-methyl-D-aspartate (NMDA) receptor complex. In the [3H]glycine binding assay (E)-4

  新型（E）-3-（2-（N-苯基氨基甲酰基）-乙烯基）吡咯-2-羧酸在4-和5-上带有烷基，酰基，烷氧基，苯基和卤素取代基的合成及初步生物学评价报告了吡咯环的位置。研究了这些化合物在N-甲基-D-天冬氨酸（NMDA）受体复合物的对苯丙氨酸不敏感的甘氨酸结合位点的体外亲和力。在[3H]甘氨酸结合测定中，（E）-4,5-二溴-3-（2-（N-苯基氨基甲酰基）乙烯基）吡咯-2-羧酸6w（pKi = 7.95 +/- 0.01）和4-溴5-甲基6j（pKi = 7.24 +/- 0.01）和4,5-二甲基6g（pKi = 6.70 +/- 0.03）类似物是该系列中活性最高的化合物。定性结构活性分析指出C-4和C-5取代基的体积与亲和力之间呈负相关，而卤素取代基增强了亲和力。通过Hansch描述符F，R，pi和MR对pKi>或= 4的化合物子集进行的QSAR分析表明，C-4和C-5处的吸电子基团增
• INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan Michele L. R.

  公开号：US20100029737A1

  公开（公告）日：2010-02-04

  The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

  本发明提供了新型D-氨基酸氧化酶酶的抑制剂。本发明的化合物可用于治疗或预防疾病和/或症状，其中调节D-丝氨酸水平和/或其氧化产物对缓解症状有效。本发明还提供了增强学习，记忆和/或认知的方法。例如，本发明提供了用于治疗或预防神经退行性疾病（如阿尔茨海默病）相关的记忆和/或认知丧失的方法。本发明还提供了预防神经退行性疾病特征性神经元功能丧失的方法。此外，还提供了用于治疗或预防神经精神疾病（例如，精神分裂症）和用于治疗或预防疼痛和共济失调的方法。
• Inhibitors of D-amino acid oxidase
  申请人：Sepracor, Inc.

  公开号：US07902252B2

  公开（公告）日：2011-03-08

  The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

  本发明提供了新型D-氨基酸氧化酶的抑制剂。本发明的化合物可用于治疗或预防疾病和/或症状，其中调节D-丝氨酸水平及/或其氧化产物可有效缓解症状。此外，本发明还提供了增强学习、记忆和/或认知的方法。例如，本发明提供了用于治疗或预防神经退行性疾病（如阿尔茨海默病）相关的记忆和/或认知损失的方法。本发明还提供了预防神经退行性疾病特征性神经元功能丧失的方法。此外，还提供了治疗或预防神经精神疾病（如精神分裂症）以及治疗或预防疼痛和共济失调的方法。
• PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP2460794A1

  公开（公告）日：2012-06-06

  The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R1 is substituted or unsubstituted alkyl, etc., W is -O-, etc., n is an integer of 0 to 6; X is N(R7)- or -O-; R7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is-C(R8)= or -N=; R8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is =O, =S, etc.; B ring is a ring represented by the following formula wherein R10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R11, R12a and R12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.

  本发明提供了一种具有组胺 H4 受体调节活性的化合物。 由式（I）代表的化合物： 其中 一个环是由下式表示的环： 其中 R1是取代或未取代的烷基等，W是-O-等，n是0至6的整数；X是N(R7)-或-O-；R7是氢、取代或未取代的烷基等；Y是-C(R8)=或-N=；R8是氢、取代或未取代的烷基等；Z是=O、=S等； B 环是由下式表示的环 其中 R10各自独立地为取代或未取代的烷基、卤素、羟基、取代或未取代的烷氧基、取代或未取代的氨基；R11、R12a和R12b各自独立地为氢或取代或未取代的烷基等；p为0至4的整数，或其药学上可接受的盐，或其溶液。